标题
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-07-20
DOI
10.1038/s41571-021-00532-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Andrés Poveda et al. LANCET ONCOLOGY
- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
- (2020) Adrienne G. Waks et al. ANNALS OF ONCOLOGY
- Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
- (2020) Bhavana Pothuri et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors
- (2020) Neelima Vidula et al. CLINICAL CANCER RESEARCH
- PARP and PARG inhibitors in cancer treatment
- (2020) Dea Slade GENES & DEVELOPMENT
- TRIP13 regulates DNA repair pathway choice through REV7 conformational change
- (2020) Connor S. Clairmont et al. NATURE CELL BIOLOGY
- PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1
- (2020) Rimma Belotserkovskaya et al. Nature Communications
- TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
- (2020) Nadine M. Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis for allosteric PARP-1 retention on DNA breaks
- (2020) Levani Zandarashvili et al. SCIENCE
- Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA
- (2020) T. Grellety et al. ANNALS OF ONCOLOGY
- A Genetic Map of the Response to DNA Damage in Human Cells
- (2020) Michele Olivieri et al. CELL
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- Oncometabolites suppress DNA repair by disrupting local chromatin signalling
- (2020) Parker L. Sulkowski et al. NATURE
- Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
- (2020) Hyoung Kim et al. Nature Communications
- Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
- (2020) Timothy A. Yap et al. Cancer Discovery
- Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells
- (2020) Hiroaki Nagashima et al. Cancer Discovery
- Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance
- (2020) Stephen J. Pettitt et al. Cancer Discovery
- ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
- (2020) R.E. Miller et al. ANNALS OF ONCOLOGY
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP-ribose) polymerase inhibition: past, present and future
- (2020) Nicola J. Curtin et al. NATURE REVIEWS DRUG DISCOVERY
- Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining
- (2020) Paola Francica et al. Cell Reports
- Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
- (2020) Yao Xiong et al. NEOPLASIA
- Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
- (2020) David A. Wheeler et al. CANCER CELL
- Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials
- (2019) Lei Wang et al. CANCER SCIENCE
- Exploring and comparing adverse events between PARP inhibitors
- (2019) Christopher J LaFargue et al. LANCET ONCOLOGY
- Rad52 prevents excessive replication fork reversal and protects from nascent strand degradation
- (2019) Eva Malacaria et al. Nature Communications
- NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
- (2019) Chunjing Bian et al. Nature Communications
- BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation
- (2019) Dali Zong et al. MOLECULAR CELL
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
- (2019) Yong Fang et al. CANCER CELL
- DNA sensing by the cGAS–STING pathway in health and disease
- (2019) Mona Motwani et al. NATURE REVIEWS GENETICS
- DNA double-strand break repair-pathway choice in somatic mammalian cells
- (2019) Ralph Scully et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
- (2019) Hubert Fleury et al. Nature Communications
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
- (2019) Michael Friedlander et al. LANCET ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast cancer
- (2019) Nadia Harbeck et al. Nature Reviews Disease Primers
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
- (2019) Mansoor Raza Mirza et al. LANCET ONCOLOGY
- 53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination
- (2019) Elsa Callen et al. MOLECULAR CELL
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- 53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy
- (2019) Iris Eke et al. NUCLEIC ACIDS RESEARCH
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells
- (2018) Hélène Marijon et al. BIOMEDICINE & PHARMACOTHERAPY
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
- (2018) Rajat Gupta et al. CELL
- The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer
- (2018) Alice Lallo et al. CLINICAL CANCER RESEARCH
- FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1‐defective cells
- (2018) Junya Tomida et al. EMBO JOURNAL
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
- (2018) Hana Hanzlikova et al. MOLECULAR CELL
- Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
- (2018) Harveer Dev et al. NATURE CELL BIOLOGY
- Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair
- (2018) Parker L. Sulkowski et al. NATURE GENETICS
- The long tail of oncogenic drivers in prostate cancer
- (2018) Joshua Armenia et al. NATURE GENETICS
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Target engagement imaging of PARP inhibitors in small-cell lung cancer
- (2018) Brandon Carney et al. Nature Communications
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
- (2018) Jone Michelena et al. Nature Communications
- Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
- (2018) Katherine Sullivan-Reed et al. Cell Reports
- The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
- (2018) Marco Barazas et al. Cell Reports
- Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study
- (2018) Theresa L. Werner et al. Cancer Medicine
- SHLD2/FAM35A co‐operates with REV7 to coordinate DNA double‐strand break repair pathway choice
- (2018) Steven Findlay et al. EMBO JOURNAL
- QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
- (2018) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- High speed of fork progression induces DNA replication stress and genomic instability
- (2018) Apolinar Maya-Mendoza et al. NATURE
- CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
- (2018) Michal Zimmermann et al. NATURE
- 53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ
- (2018) Hind Ghezraoui et al. NATURE
- The shieldin complex mediates 53BP1-dependent DNA repair
- (2018) Sylvie M. Noordermeer et al. NATURE
- 53BP1–RIF1–shieldin counteracts DSB resection through CST- and Polα-dependent fill-in
- (2018) Zachary Mirman et al. NATURE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- An OB-fold complex controls the repair pathways for DNA double-strand breaks
- (2018) Shengxian Gao et al. Nature Communications
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- (2018) Olga Kondrashova et al. Nature Communications
- BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
- (2018) Joseph Nacson et al. Cell Reports
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors
- (2018) Marco Barazas et al. CANCER RESEARCH
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
- (2018) Yizhou Joseph He et al. NATURE
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
- (2018) Jordan R. Becker et al. Nature Communications
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
- (2018) Kaiming Sun et al. Oncotarget
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies
- (2017) Nathalie van den Tempel et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery
- (2017) Juhong Jiang et al. INVESTIGATIONAL NEW DRUGS
- A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair
- (2017) Rossella Parrotta et al. Journal of Thoracic Oncology
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
- (2017) Leslie A. Parsels et al. MOLECULAR CANCER RESEARCH
- Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
- (2017) Sani H. Kizilbash et al. MOLECULAR CANCER THERAPEUTICS
- Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
- (2017) Angelo Taglialatela et al. MOLECULAR CELL
- RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks
- (2017) Huzefa Dungrawala et al. MOLECULAR CELL
- Smarcal1-Mediated Fork Reversal Triggers Mre11-Dependent Degradation of Nascent DNA in the Absence of Brca2 and Stable Rad51 Nucleofilaments
- (2017) Arun Mouli Kolinjivadi et al. MOLECULAR CELL
- TIRR regulates 53BP1 by masking its histone methyl-lysine binding function
- (2017) Pascal Drané et al. NATURE
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- Non-homologous DNA end joining and alternative pathways to double-strand break repair
- (2017) Howard H. Y. Chang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
- (2017) Lu Yang et al. Science Translational Medicine
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Proteomic analyses identify ARH3 as a serine mono-ADP-ribosylhydrolase
- (2017) Jeannette Abplanalp et al. Nature Communications
- MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells
- (2017) Xianning Lai et al. Nature Communications
- Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
- (2017) Pepijn M. Schoonen et al. Nature Communications
- MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells
- (2017) Delphine Lemaçon et al. Nature Communications
- Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions
- (2017) Susan M. Domchek Cancer Discovery
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
- (2017) C. Allison Stewart et al. Oncotarget
- BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
- (2017) Sergey Karakashev et al. Cell Reports
- A PALB2-interacting domain in RNF168 couples homologous recombination to DNA break-induced chromatin ubiquitylation
- (2017) Martijn S Luijsterburg et al. eLife
- Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
- (2016) R.S. Kristeleit et al. ANNALS OF ONCOLOGY
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- PARP inhibitors: the race is on
- (2016) Jessica S Brown et al. BRITISH JOURNAL OF CANCER
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
- (2016) Jonathan A Ledermann et al. LANCET ONCOLOGY
- HELB Is a Feedback Inhibitor of DNA End Resection
- (2016) Ján Tkáč et al. MOLECULAR CELL
- Mammalian RAD52 Functions in Break-Induced Replication Repair of Collapsed DNA Replication Forks
- (2016) Sotirios K. Sotiriou et al. MOLECULAR CELL
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
- (2016) Xia Ding et al. Nature Communications
- PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2BGlu2
- (2016) Gabrielle J. Grundy et al. Nature Communications
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
- (2016) Shawn F. Johnson et al. Cell Reports
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
- (2015) Kensuke Tateishi et al. CANCER CELL
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- The rise and fall of poly(ADP-ribose): An enzymatic perspective
- (2015) John M. Pascal et al. DNA REPAIR
- Resistance to therapy inBRCA2mutant cells due to loss of the nucleosome remodeling factor CHD4
- (2015) Shawna Guillemette et al. GENES & DEVELOPMENT
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection
- (2015) Vera Boersma et al. NATURE
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
- (2015) Raphael Ceccaldi et al. NATURE
- Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
- (2015) Pedro A. Mateos-Gomez et al. NATURE
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
- (2015) J. Shen et al. Cancer Discovery
- Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
- (2015) Young Eun Choi et al. Oncotarget
- Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer
- (2014) Felix Y. Feng et al. BREAST CANCER RESEARCH AND TREATMENT
- Germline Mutations in BAP1 Impair Its Function in DNA Double-Strand Break Repair
- (2014) I. H. Ismail et al. CANCER RESEARCH
- BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
- (2014) J. E. Jaspers et al. CANCER RESEARCH
- Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
- (2014) Panagiotis A. Konstantinopoulos et al. GYNECOLOGIC ONCOLOGY
- Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
- (2014) Poorval M. Joshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CtIP-mediated resection is essential for viability and can operate independently of BRCA1
- (2014) Federica Polato et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
- (2014) O. S. Chao et al. MOLECULAR CANCER RESEARCH
- PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
- (2014) Marie-France Langelier et al. NUCLEIC ACIDS RESEARCH
- BRCA1 Accelerates CtIP-Mediated DNA-End Resection
- (2014) Andrés Cruz-García et al. Cell Reports
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- 53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions
- (2013) Elsa Callen et al. CELL
- Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
- (2013) J. E. Ang et al. CLINICAL CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair
- (2013) Lin Feng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression
- (2013) Colleen R. Reczek et al. JOURNAL OF CELL BIOLOGY
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
- (2013) J. Ross Chapman et al. MOLECULAR CELL
- A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice
- (2013) Cristina Escribano-Díaz et al. MOLECULAR CELL
- Quantitation of DNA double-strand break resection intermediates in human cells
- (2013) Yi Zhou et al. NUCLEIC ACIDS RESEARCH
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 53BP1 Regulates DSB Repair Using Rif1 to Control 5' End Resection
- (2013) M. Zimmermann et al. SCIENCE
- Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
- (2013) M. Di Virgilio et al. SCIENCE
- Visualization of poly(ADP-ribose) bound to PARG reveals inherent balance between exo- and endo-glycohydrolase activities
- (2013) Eva Barkauskaite et al. Nature Communications
- A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
- (2012) Katharina Schlacher et al. CANCER CELL
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
- (2012) S. Ying et al. CANCER RESEARCH
- RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1
- (2012) S. Nakada et al. CANCER RESEARCH
- Mutational Processes Molding the Genomes of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
- (2012) Péter Bai et al. Cell Metabolism
- Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
- (2012) Ilirjana Bajrami et al. EMBO Molecular Medicine
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
- (2012) Elisabet Wahlberg et al. NATURE BIOTECHNOLOGY
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- CHFR is important for the first wave of ubiquitination at DNA damage sites
- (2012) Chao Liu et al. NUCLEIC ACIDS RESEARCH
- RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination
- (2012) B H Lok et al. ONCOGENE
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
- (2011) Katharina Schlacher et al. CELL
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter
- (2011) Y. Lu et al. MOLECULAR AND CELLULAR BIOLOGY
- PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
- (2011) Stuart L. Rulten et al. MOLECULAR CELL
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- BRCA1 tumour suppression occurs via heterochromatin-mediated silencing
- (2011) Quan Zhu et al. NATURE
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition
- (2011) P. M. Krawczyk et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
- (2010) R A Daniel et al. BRITISH JOURNAL OF CANCER
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways
- (2010) Riekelt H. Houtkooper et al. ENDOCRINE REVIEWS
- PARP-3 Is a Mono-ADP-ribosylase That Activates PARP-1 in the Absence of DNA
- (2010) Olga Loseva et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
- (2010) C. E. Strom et al. NUCLEIC ACIDS RESEARCH
- Rad52 inactivation is synthetically lethal with BRCA2 deficiency
- (2010) Z. Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors
- (2009) B. Evers et al. CLINICAL CANCER RESEARCH
- Radiation-induced mitotic catastrophe in PARG-deficient cells
- (2009) J.-C. Ame et al. JOURNAL OF CELL SCIENCE
- A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency
- (2009) Liu Cao et al. MOLECULAR CELL
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation